Aducanumab, or Aduhelm, is the first new Alzheimer’s treatment in 18 years and the first to attack the disease process. But some prominent experts say there’s not enough evidence it can address cognitive symptoms.
from NYT > Top Stories https://ift.tt/3gieUPg
June 08, 2021 at 12:14AM
0 Comments